R Paridaens
Overview
Explore the profile of R Paridaens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
143
Citations
1511
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Decock J, Obermajer N, Vozelj S, Hendrickx W, Paridaens R, Kos J
Int J Biol Markers
. 2008 Oct;
23(3):161-8.
PMID: 18949742
Numerous studies have linked cathepsins and their inhibitor cystatin C to tumor invasion and metastasis. We examined whether cathepsin B, cathepsin H, cathepsin X and cystatin C could be detected...
22.
Brouwers B, Paridaens R, Lobelle J, Hendrickx W, Smeets A, Neven P, et al.
Tumour Biol
. 2008 Sep;
29(4):211-6.
PMID: 18781092
Background: Inflammatory breast cancer (IBC) is a rare but aggressive form of breast cancer. It is mainly a clinical diagnosis. The aim of this study was to compare IBC to...
23.
Wildiers H, Dirix L, Neven P, Prove A, Clement P, Squifflet P, et al.
Breast Cancer Res Treat
. 2008 Mar;
114(1):103-12.
PMID: 18344024
Introduction: This study prospectively investigates the impact of dose densification and altering sequence of fluorouracil, epirubicin and cyclophosphamide [FEC(100)] and docetaxel [Doc] on dose delivery and tolerability of adjuvant chemotherapy...
24.
Decock J, Paridaens R, Ye S
Clin Genet
. 2008 Jan;
73(3):197-211.
PMID: 18177467
The matrix metalloproteinases (MMPs) can degrade various components of the extracellular matrix and are implicated in the development and progression of cancer. There is evidence suggesting an association of MMP...
25.
Venturini M, Paridaens R, Rossner D, Vaslamatzis M, Nortier J, Salzberg M, et al.
Oncology
. 2007 Nov;
72(1-2):51-7.
PMID: 18004077
Background: Phase II/III trials have shown that capecitabine is an active, well-tolerated therapy for metastatic breast cancer (MBC). We report clinical findings from an expanded access program enabling patients ineligible...
26.
Neven P, Van Calster B, Van den Bempt I, Van Huffel S, Van Belle V, Hendrickx W, et al.
Breast Cancer Res Treat
. 2007 Aug;
110(1):153-9.
PMID: 17687649
Background: The negative association between the oestrogen receptor (ER) and the human epidermal growth factor receptor 2 (HER-2) in breast cancer travels in both directions. ER+ tumours are less likely...
27.
Decock J, Hendrickx W, Drijkoningen M, Wildiers H, Neven P, Smeets A, et al.
Dis Markers
. 2007 May;
23(3):189-96.
PMID: 17473389
Objective: Aberrant expression of individual matrix metalloproteinases has been associated with poor prognosis in various human carcinomas. The current study aimed at defining an RNA expression profile of various MMPs...
28.
Coombes R, Kilburn L, Snowdon C, Paridaens R, Coleman R, Jones S, et al.
Lancet
. 2007 Feb;
369(9561):559-70.
PMID: 17307102
Background: Early improvements in disease-free survival have been noted when an aromatase inhibitor is given either instead of or sequentially after tamoxifen in postmenopausal women with oestrogen-receptor-positive early breast cancer....
29.
Mauriac L, Keshaviah A, Debled M, Mouridsen H, Forbes J, Thurlimann B, et al.
Ann Oncol
. 2007 Feb;
18(5):859-67.
PMID: 17301074
Background: Aromatase inhibitors are considered standard adjuvant endocrine treatment of postmenopausal women with hormone receptor-positive breast cancer, but it remains uncertain whether aromatase inhibitors should be given upfront or sequentially...
30.
Van Mieghem T, Leunen K, Pochet N, Moor B, De Smet F, Amant F, et al.
Breast Cancer Res Treat
. 2007 Jan;
106(1):127-33.
PMID: 17211534
Purpose: In breast cancer, in vitro as well as in vivo experiments have shown an inverse relationship between HER-2 and steroid hormone receptors. It is unknown whether circulating estrogens affect...